Comments (0)
Trackbacks (0)
Leave a comment
Trackback
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
Mastering the origins of conviction, one key stroke at a time
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.
Recent Posts
- I want to get Stemmed, not Zucked!
- As FB embarrasses, time for Stem Cell spotlight comeback
- RegMed Daily, Closing Bell, 5/21/12, Can the sector break out of its funk??
- Intellicell Biosciences (SVFC.PK) Off-Balance Sheet triggers Default
- RegMed Competitive and Market Intelligence 5/21/12, OSIR climbs as FB drops
Categories
- $16.7M to Fund CLT-008 for ARS
- $3M Award to Develop Gene
- 18 month outcomes from its APOLLO trial
- A Daily Look
- Aastrom Biosciences
- Acquisition
- ACTC.OB
- ACTCellerate™ Cell Lines
- Acute Mycardial Infaraction (AMI) Update and Review
- Acute Radiation Syndrome (ARS)
- adult stem cells
- Advanced Cell Technology
- advocacy coalition
- AFIRM
- AHA Update
- Alchemia (ASX: ACL)
- Aldagen
- Aldargen
- Alliance Defense Fund
- Allogeneic cell-based therapy
- ALS Clinical Trial
- Alzheimer's disease
- AMEX: BTX
- AMEX: CUR
- AMEX: NBS
- Amicus Brief
- Amicus Curiae Filing
- An Expanded Market Oppurtunity
- An extra $1B for the NIH?
- An Objective Opinion
- Anaplastic Thyroid Cancer
- AnC Bio Holdings
- Angelman Syndrome
- Angiochem
- APOLLO study
- APOLLO Trial demonstrated Safety & Feasibility and Improvements in Cardiac Function
- ASTM
- ASX: MSB
- At-the-Market (ATM) Offerings
- Athersys (ATHX)
- Athersys (NASDAQ: ATHX)
- Autologous cell therapy
- basal cell carcinomas (BCCs)
- Batten disease
- BAXTER
- Baxter Ventures
- BBRI
- Bio Medicine
- Bioheart (OTCBB: BHRT)
- Biomedical CEO survey
- Biomet Biologics
- BioMimetic Therapeutics
- BioMimetic Therapeutics (BMTI)
- Biopolymer Microthreads
- Biotech Leads by Percentage in Q/2/10
- Biotechnology Tax Breaks
- BioTime (AMEX:BTX)
- BLA Approval
- Bluebird bio
- Boston Biomedical Research Institute
- Brainstorm Therapeutics (BCLI.OB)
- California Institute for Regenerative Medicine (CIRM)
- cancer
- Cancer Costs to rise as US Population Ages
- cancer research
- cancer stem cells
- Capricor
- CAR Gene
- Cardiac Cell Therapy webcast
- Cardio3 BioSciences
- Cardiovascular Licensing Agreement
- Cedars-Sinai Regenerative Medicine Institute
- Cell Therapy Companies
- Cellectis SA to acquire Cellartis
- Cellerant Therapeutics
- Cellular Dynamics
- Cellular origins of breast cancer
- Cephalon (CEPH)
- Cevec Pharmaceuticals
- Chemistry Nobel Prize
- Clinical Data from GRNOPC1 Spinal Cord Injury Trial
- Clinical Hold Lifted
- Clinical Trial for DCM
- Clinical Trial for multiple sclerosis-related fatigue (PMSF)
- Co-promotion Sales Agreement
- Collaboration
- Collaboration and License Agreement
- Collaborative Research
- Colon Cancer and detecting Relapse
- Columbia University Medical Center
- commercial sale in India
- Complete sequencing of DNA shows normality of the cells and their suitability for clinical use
- Cord Blood Banks
- Cord Blood Stem Cell Adaptation
- Cord Blood Stem Cells
- Credit Downgrade
- critical limb ischemia
- Crohn's Disease Colitis Model
- Cytomedix (OTC BB:CMXI)
- Cytori Therapeutics
- Cytori's PRECISE trial
- Cytovis
- CYTX
- CYTX – Strong BUY
- CYTX earnings call
- CYTX Shareholder Letter
- Daily Look EOD Closing Bell
- Daily Look Starting the Day
- Death of Chairman and CEO
- Defense Advanced Research Projects Agency (DARPA)
- Definitive Merger Agreement
- Dendreon (DNDN)
- Diabetes
- Dickey-Wicker amendment
- DOD Award to treat Osteoporosis
- DOD Contract for Brain Cancer Research
- Dosing of HuCNS-SC in PMD Trial completed
- Dry AMD
- Early-stage Phase I trial
- Earnings Conference Call
- Earnings Report Card
- EB66 duck stem cell technology
- effective treatment for malignant glioma
- elimination and reductions of debt
- embryonic stem cell research
- Encapsulation and Stem Cell Technologies
- Epigenetics
- equity investment of $7.1M
- EU CE Mark
- European Medicines Agency (EMA)
- Exclusive license agreement
- Expands P2 Trial of ICT-107
- Extension of Warrant Expiration Date
- Fate Therapeutics
- FDA Approves First Cord Blood Product
- FDA Clearance for P3 Bone Marrow Transplant Trial
- FDA Fast Track Designation
- Fetal stem cell transplants
- Fibrocell Science
- Finalizes Amorcyte Acquisition
- Financing
- financings
- First ADVANCE trial site to begin enrollment in the Netherlands
- First Clinical Trial using hESCs
- First Patients enrolled in 2 Clinical Trials to treat Stargardt's Disease and Dry Age Macular Degeneration
- Food and Drug Administration (FDA)
- Forecast Issues
- FOXM1 gene
- French Muscular Dystrophy Association (AFM)
- Fresenius Biotech
- Fresenius Biotech’s ATG
- Frozen Blood from Stored Samples
- Fy10 earnings and recap
- FY10 Results
- FY11 & FY12 Achievements and Highlights
- FY11 Results
- Gene Test finds Disease Risk
- Gene Therapy
- Generating Platelets using iPSCs
- Generation of functional dopaminergic neuronal cells
- Genetic Mechanism
- Genetics Policy Institute (GPI)
- GERN
- Geron (GERN)
- GRABM-L (GR N1005 against B rain M etastases – L ung cancer)
- Grant for type 1 diabetes research
- GRN1005 P2 Trial
- GRN163L preclinical data
- Growing back a damaged spine
- Growing blood vessels from human tissues
- Growing heart cells
- Growing New Replacement Joints
- H.R. 6165
- Haemopoietic Stem Cells
- Hamilton Thorne Ltd. (TSX-V: HTL)
- Happy New Year 2011
- Happy New Year 2012
- Happy Thanksgiving
- Harris Interactive/HealthDay poll
- Harvard Scientists Report
- Harvest Technologies’
- Healthcare
- Healthcare VC continues to Slide
- Heated gold nanoshells
- Henry W McCusker
- hESC development
- hESC funding Controversy
- hESCs to treat SMD
- Histogenics
- HIV Therapy Findings
- Holiday Achievement
- House Republicans
- HR 6081
- HR 6081 Renewed
- http://www.scimitarequity.com/blog/wp-admin/user-new.php
- Human Cardiomyocyte Product Launches
- Human Stem Cells used to treat Parkinson's
- IBD Phase II Clinical Trial
- IDE clinical trial
- imetelstat (GRN163L)
- Immune Matched Human Parthenogenetic Stem Cells
- ImmunoCellular Therapeutics
- IMUC.OB
- In-house screening of compound libraries
- In-License of Patent Portfolio
- IND Application Cleared
- IND Approval for Major Depression Trial
- IND Filed
- IND for SMD
- Independent Equity Research
- Independent Insight
- induced pluripotent stem (iPS) cells
- induced pluripotent stem cells technology
- initiates P2 Trial of GRN1005
- Initiates PSTI with a Speculative "BUY" rating
- Initiation Phase II Trial
- intellectual property deals
- IntelliCell (OTCQB: SVFC)
- Interim Results
- Interim results from ASTM’s US Phase 2b RESTORE-CLI trial
- International Stem Cell (ISCO.OB)
- Intestinal Tissue
- iPierian
- iPS Cell Patent in-licensed
- iPS Cell Patents
- iPS-derived heart cells
- IRB Approval
- Is Dilution the only Solution?
- ischemic stroke
- Ischemic Tolerant Stem Cells
- ISCO.OB
- James Sherley
- Join our Community
- Joint Venture
- Juventas Therapeutics
- Karolinska Institutet
- Key Catalysts and Milestones
- Key factors driving growth in stem cells research
- Lack of Funding Stability
- leukemia
- License
- Licenses a clinically active oncology vaccine
- Life Sciences Jobs and Investment Act of 2010
- Lifeline Skin Care ™.
- Lin28
- livers from stem cells
- LON: RENE
- Long QT syndrome
- Macular Degeneration
- Major Luis Alvarez
- Management Change
- Marketing Agreement
- Maryland Stem Cell Research Commission issues 2012 Requests for Applications (RFAs)
- Maryland Stem Cell Research Fund
- Mass Companies
- Matched maternal blood cells
- Material Transfer Agreement
- Medical College of Wisconsin
- Medistem (MEDS.PK)
- Medtronic (MDT) participated
- MELA Sciences (MELA)
- Memorandum of Understanding
- Merger Agreement
- Merger Negotiations Terminated
- Merger of Glycosan BioSystems
- Merry Christmas
- Mesoblast (ASX: MSB)
- Mesoblast Ltd
- Michael J. Fox Foundation
- miR-34a
- Mirna Therapeutics
- Momentum and Appreciation
- Motor Neurone Disease Research
- MSC's
- MultiStem
- MultiStem therapy for treating stroke
- Muscular Dystrophy
- Myoblast program
- NANEX
- NASDAQ Compliance
- NASDAQ Listing Issue
- NASDAQ: ACTC.OB
- NASDAQ: ASTM
- NASDAQ: ATHX
- Nasdaq: BCLI.OB
- NASDAQ: CYTX
- NASDAQ: FSC.OB
- NASDAQ: GERN
- NASDAQ: IMUC.OB
- NASDAQ: ISCO.OB
- NASDAQ: KOOL
- NASDAQ: LFE
- NASDAQ: OSIR
- NASDAQ: PSTI
- NASDAQ: STEM
- NASDAQ: STEMD
- NASDAQ: TNGN
- NASDAQ:OPXA
- National Institute of Health(NIH)
- National Securities
- National Securities Corp
- National Securities Downgrade
- National Venture Capital Association (NVCA)
- Nature Biotechnology article
- NBS and Progenitor Cell Therapy (PCT) closed their merger transaction.
- NBS’s Progenitor Cell Therapy (PCT)
- Need for frequent genomic monitoring of pluripotent stem cells
- Neo-Urinary Conduit
- NeoStem
- NeoStem (AMEX: NBS)
- Nerve Regeneration
- Neural Stem Cell Therapy
- Neuralstem (AMEX:CUR)
- Neuralstem (AMEX; CUR)
- New ASTM Analyst Review
- New board member
- New Cell Banking Services
- New Cell Lines
- New Cell Lines for Research
- New CEO and Board Member
- New Chairman
- New Chairman & CEO
- New Chairman of CIRM
- New Collaboration
- New COO and acting CEO
- New CYTX Analyst Review
- New Distribution Agreement
- New Embryome Products
- New FDA Reporting Rules
- New Findings
- New Foundational Japanese Patent
- New interim CEO
- New Lead Investor Google Ventures
- New Patent
- New Proxy
- New Scientific Advisory Board Member
- new test for genetic mutations
- New Therapeutic Approach
- New Trial Results
- New Venture Financing
- News from Global Stem Cell Summit
- NHLBI Grant using iPSCs
- NIH Budget
- NIH Funding for Clinical Trials
- Nobel Prize in Medicine
- Non-exclusive international license
- Non-exclusive license
- NSI-189 IND Application
- NSI189 Safety Depressive Disorder Trial
- NurOwn™ inhibits Sciatic Nerve Injury
- Nuvilex (OTC QB: NVLX)
- NYSE Amex: BTIM
- NYSE Amex: NBS
- OncoCyte Corporation
- Opening the Door to India
- Opexa Therapeutics (OPXA)
- Opinion
- Orphan Drug designation
- Orphan Drug Designation (ODD)
- Orphan Drug Status
- Orthopedic Collaboration
- orthopedic regenerative medicine/biotechnology company
- OSIR Rebounds
- OSIR strengthens mngt team
- OSIR trends higher again
- Osiris Therapeutics
- OTC:BB:ACTC
- P1 Heart attack trial of its stem cell therapy
- P1 PISCES safety clinical trial
- P2 imetelstat (GRN163L) trial
- P2b RESTORE-CLI Webcast
- P3 study of HA-Irinotecan in metastatic colorectal (bowel) cancer
- Parkinson disease
- Parthenogenesis could treat Inherited Disease
- Parthenogenetic Stem Cell Patent
- Partners with Vatican’s Pontifical Council
- Patent and know-how license agreement with Schepens Eye Research Institute
- Patent Issuance
- Patent Issues
- Patent trouble Ahead?
- Patents
- Patient Enrollment in REVIVE P3 Clinical Trial of Ixmyelocel-T
- Patient Protection and Affordable Care Act of 2010
- Patients with head and neck cancers
- Pay OK for Blood-Based Marrow Cell Donors
- Pelizeaus-Merzbacher Disease (PMD)
- peripheral arterial disease
- Personalized Medicine
- personalized treatment.
- Phase 2 IMPACT-DCM clinical trial extension study
- Phase I clinical trial of MultiStem(R)
- Phase I/II trial
- Phase Ib trial
- Phase II trial clearence
- Phase II/III Clinical Trial in CLI Advances
- Phase IIb TERMS clinical trial
- PI dendritic cell cancer clinical trial
- PI Study of MultiStem
- PII clinical trial for stroke
- Plasticell
- pluripotent stem cell patents
- pluripotent stem cell products
- pluripotent stem cells
- Pluristem (PSTI)
- Pluristem Therapeutics
- Politics
- Positive 12-month final results from the RESTORE-CLI Phase 2 clinical trial
- Positive clinical trials of its adult stem cell product
- Positive Interim Safety Data from Spinal Cord Injury Trial
- Positive P2 Data for Autologous Treatment
- Positive Pre-Clinical Data from Muscle Injury Study
- Positive Results from Phase I Study of MultiStem(R) in Heart Attack Patients
- Positive Results of Bone Marrow Regeneration Trial
- Potential targets for new cancer drugs
- Potential Treatment of Radiation Exposure
- PPACA Grant
- Prader-Willi Syndrome
- pre-CTA consultation meeting
- Preclinical Acute Kidney Injury Study
- Preclinical Results
- Preclinical Study Data of GRNCM1
- Printing Human Skin
- Product Aquisitions
- Progenitor Cell Therapy (PCT) adds to Management
- Promise for Epileptics
- Proposed Public Offering
- Prospectus to register Shares
- Prostate Cancer
- protein-induced pluripotent stem (iPS) cells
- Proteins Found in Muscle Tissue
- Provide stem cell and cancer researchers with leading-edge technologies
- Proxy for Reverse Split
- Prudent Shelf Filing
- Public offering
- Public Offering closes
- Public Offering Completed
- purchase warrants offered
- PureGraft™ System
- Purifying Embryonic Stem Cells
- PwC/NVCA MoneyTree Report
- Q1/11 Results
- Q1/12 Earngs
- Q2 Earnings
- Q2/11 earnings
- Q3/10 Results
- Q3/10 Venture Funding
- Q3/11 Results
- Q4/10 and FY/10 Results
- Q4/10 results
- Q4/11 and FY 11 Results
- Q4/11 and FY11 Results
- QTDP grants
- Qualifying Therapeutic Discovery Program (QTDP)
- Qualifying Therapeutic Discovery Project
- Quarterlly Achievements
- Quarterly Achievements
- Quarterly Earnings
- Radiation exposure
- Re-nominating Process
- Re-nomination of Bob Klein
- Red Blood Cells from IVF Embryos
- Refocusing cancer research
- Regenerative benefits of MultiStem's therapy
- Regenerative Medicine
- Regenerative Medicine Mid-Week Trend Line
- Regenerative Medicine Promotion Act of 2010
- Regenerative Medicine Weekly Trend Line
- REGENESIS-Phase IIb stroke trial
- Registered Direct Offering
- RegMed Competitive and Market Intelligence
- RegMed Daily
- RegMed Daily Closing Bell
- RegMed Daily Dialogue
- RegMed Daily Mid-Day
- RegMed Daily Pre-Open
- ReNeuron (LON: RENE)
- ReNeuron (LSE:RENE.L)
- Reneuron Group
- ReNeuron Group (RENE.L)
- Repairing cardiac muscles
- Replicating Real Skin
- Replicating the complexity of an organ
- Report Card
- Res-Q™60 BMC System
- Research Note
- Researchers need reliable stem-cell supplies
- Restatement Reclassifies Warrants
- RESTORE-2 study
- RESTORE-CLI trial
- Restoring Partial Spine Mobility
- Retinal Disease Studies
- retinal pigment epithelium (RPE)
- Revascor (TM)
- Reverse stock split
- rheumatoid arthritis
- Roche
- Roche and UCLA Agreement
- Rod Raynovich – Contributor
- Salk Institute for Biological Studies
- Sangamo Biosciences (SGMO)
- SC Proven product Portfolio
- Scale-up initiated
- Science Briefs
- SCRO Approval
- Sector Analysis
- Secured Loan Facility
- Sept4/ARTS pathway
- Series B Venture Financing
- Setback for New Stem Cell Treatment
- Settleing errors involving warrant issuances
- Shelf Filing up to $75M
- Sherley v. Sebelius
- Sherley v. Sebelius case
- Shire
- Shutting down cell division could lead to new cancer drugs.
- Sigma-Aldrich
- Signaling Pathways
- Single-blastomere technology Patent
- Skin Rejuvenation Crèmes
- Sox9
- SPA Agreement
- SPA submitted to FDA
- special protocol assessment (SPA) process
- Spinal Cord Injury Trial
- Stem Cell Banking
- Stem cell breakthrough
- Stem Cell centers for Innovation
- Stem Cell Data to Repair Brain Damage
- Stem cell differentiation protocols
- Stem Cell Disorders
- Stem Cell Gene Linked to Leukemia and Other Cancers
- Stem Cell Line Litigation
- Stem Cell Market
- Stem Cell Research
- Stem Cell Research Advancement Act
- Stem Cell Skin Gun for wound care
- Stem Cell Study helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors
- Stem Cell Technology
- Stem Cell Therapeutic and Research Act
- Stem Cell Therapeutic and Research Reauthorization Act
- Stem Cell Therapeutics (TSX: VENTURE SSS)
- stem cell therapy for severe kidney disease
- Stem Cell Trial in Spinal Cord Injury
- Stem Cell/Regenerative Medicine Universe Earnings
- Stem cells can be targeted in their fight against liver cancer
- Stem Cells Go to War
- Stem Line Litigation
- StemCellRegenMed
- StemCells
- StemCells (STEM)
- Stemedica
- Stemedica Cell Technology
- Stemgent
- Stemline Therapeutics
- Steve Brozak
- strategic alliance
- strategic equity agreement
- Strategic Equity Agreement Closes
- Strengthened management team
- Suppressing a protein in the blood
- Supreme Court ruling
- Susan G Komen for the Cure
- SynGen
- Synthetic Biology
- Targeting Ischemic Diseases by Improving Blood Flow
- Tay-Sachs disease
- telomerase inhibitor drug
- Temusi CLI phase III Trial Fails
- Tengion
- The Alliance for Regenerative Medicine
- The Daily Dialogue
- The Daily Look
- The Intellectual Property Value
- The issue of liability claims
- The president’s proposed budget
- The RegMed Daily Dialogue
- The Roslin Institute
- The Stem Cell Therapeutic and Research Reauthorization Act of 2010
- The Trend is your Friend
- The Vatican
- The Vatican Response
- The Week: August 2-6/10
- Therapeutic Discovery Project
- Therapeutic Discovery Tax Credit
- Theresa "Tracy" Deisher
- ThermoGenesis (KOOL)
- Thomas B. Okarma Leaves as CEO
- Ticker Symbol Change
- TiGenix (NYSE Euronext: TIG)
- TiGenix (TIG) combination with Cellerix
- TiGenix combination with Cellerix
- TikoMed AB
- TNGN
- Tovaxin® for multiple sclerosis (MS)
- Tracy T. Lefteroff
- Transcription Factors play a role in maintaining Blood Stem Cells
- Transdifferentiation Platform
- Transposagen Biopharmaceuticals
- Treating bowel cancer
- Treating corneal blindness and vision impairment
- Treatment of diabetic foot ulcers and other chronic wounds
- TSX VENTURE: SSS
- UCSD Awards
- UCSF expanding hESC research
- UK Cancer Stem Cell Consortium
- UK NHS National Innovation Centre
- UMass’ Medical School's Human Stem Cell Bank and Registry
- Uncategorized
- universal red blood cells and platelets
- University of Michigan Comprehensive Cancer Center
- University of Minnesota‘s Masonic Cancer Center
- Unsolicited proposal from TSE:VRX re CEPH
- Update on Neo-Urinary Conduit Clinical Trial
- Updating Skin Care product
- US Army Grant for Traumatic Wounds
- US Court of Appeals for the District of Columbia
- US Patent and Trademark Office
- US Phase 2 IMPACT-DCM clinical trial results
- Vatican and NeoStem (AMEX: NBS) host Adult Stem Cell Meeting
- VEITHsymposium™ non-CME satellite session
- Venture Financing
- Venture series A financing from Bay City Capital LLC
- Verastem
- Verastem (NASDAQ: VSTM)
- VistaGen (OTCQB: VSTA)
- Vivalis (VLS.PA)
- VSEL™ Technology
- Wake Forest Institute for Regenerative Medicine
- Wall Street Letter
- Warrant Discount Offer
- warrant exercise
- WBB Securities
- William M. Caldwell IV
- Wired Magazine article
- Withdraws plans for IPO
- Worldwide exclusive license
- Wound Care
- www. Scimitar Equity.com/blog
- www.retailinvestorconferences.com
Blogroll
Regulatory Disclosure
Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009